This paper presents the R package bcrm for conducting and assessing Bayesian continual reassessment method (CRM) designs in Phase I dose-escalation trials. CRM designsare a class of adaptive design that select the dose to be given to the next recruited patient based on accumulating toxicity data from patients already recruited into the trial, often using Bayesian methodology. Despite the original CRM design being proposed in 1990, the methodology is still not widely implemented within oncology Phase I trials. The aim of this paper is to demonstrate, through example of the bcrm package, how a variety of possible designs can be easily implemented within the R statistical software, and how properties of the designs can be communicated to trial...
The continual reassessment method (CRM) is a popular dose-finding design for phase I clinical trials...
The continual reassessment method (CRM) is a widely used model-based design in Phase I dose-finding ...
The primary objective of phase I dose-finding trials is to determine the maximum tolerated dose (MTD...
This paper presents the R package bcrm for conducting and assessing Bayesian continual reassessment ...
This paper presents the R package bcrm for conducting and assessing Bayesian continual reassessment ...
This paper presents the R package bcrm for conducting and assessing Bayesian continual reassessmen...
This paper presents the R package bcrm for conducting and assessing Bayesian continual reassessment ...
This paper presents the R package bcrm for conducting and assessing Bayesian continual reassessmen...
Early phase, or phase I and phase II, trials are the first step in testing new medicines that have b...
Early phase, or phase I and phase II, trials are the first step in testing new medicines that have b...
The continual reassessment method (CRM) was proposed in a Bayesian framework whereby the first patie...
The continual reassessment method (CRM) was proposed in a Bayesian framework whereby the first patie...
The continual reassessment method (CRM) is a model-based design for phase I trials, which aims to fi...
Introduction The continual reassessment method (CRM) is a model-based design for phase I trials, whi...
Introduction The continual reassessment method (CRM) is a model-based design for phase I trials, whi...
The continual reassessment method (CRM) is a popular dose-finding design for phase I clinical trials...
The continual reassessment method (CRM) is a widely used model-based design in Phase I dose-finding ...
The primary objective of phase I dose-finding trials is to determine the maximum tolerated dose (MTD...
This paper presents the R package bcrm for conducting and assessing Bayesian continual reassessment ...
This paper presents the R package bcrm for conducting and assessing Bayesian continual reassessment ...
This paper presents the R package bcrm for conducting and assessing Bayesian continual reassessmen...
This paper presents the R package bcrm for conducting and assessing Bayesian continual reassessment ...
This paper presents the R package bcrm for conducting and assessing Bayesian continual reassessmen...
Early phase, or phase I and phase II, trials are the first step in testing new medicines that have b...
Early phase, or phase I and phase II, trials are the first step in testing new medicines that have b...
The continual reassessment method (CRM) was proposed in a Bayesian framework whereby the first patie...
The continual reassessment method (CRM) was proposed in a Bayesian framework whereby the first patie...
The continual reassessment method (CRM) is a model-based design for phase I trials, which aims to fi...
Introduction The continual reassessment method (CRM) is a model-based design for phase I trials, whi...
Introduction The continual reassessment method (CRM) is a model-based design for phase I trials, whi...
The continual reassessment method (CRM) is a popular dose-finding design for phase I clinical trials...
The continual reassessment method (CRM) is a widely used model-based design in Phase I dose-finding ...
The primary objective of phase I dose-finding trials is to determine the maximum tolerated dose (MTD...